Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical stage neuropsychiatry company focused on transforming mental healthcare through proprietary drug discovery and delivery technologies, announced that Chief Business Officer George Tziras will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference, scheduled for Nov. 10–12, 2025, in Boston, Massachusetts. This participation highlights Cybin's ongoing efforts to address the large unmet need for effective mental health treatments, particularly through its lead programs CYB003 and CYB004.
Cybin is developing CYB003, a proprietary deuterated psilocin analog, which is currently in Phase 3 studies for the adjunctive treatment of major depressive disorder (MDD). The drug has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to offer significant improvement over existing therapies. Additionally, Cybin is advancing CYB004, a proprietary deuterated N,N-dimethyltryptamine (DMT) molecule, in a Phase 2 study for generalized anxiety disorder (GAD). The company also maintains a research pipeline of investigational compounds focused on the 5-HT receptor system.
The Guggenheim conference provides a platform for Cybin to showcase its promising class-leading data and discuss the potential of its next-generation treatment options. With mental health conditions affecting millions worldwide, Cybin's innovative approach aims to deliver effective and durable results for patients. The company's commitment to revolutionizing mental healthcare is evident in its robust pipeline and regulatory milestones.
For more details on the press release, visit https://ibn.fm/uqBYE. Further information about Cybin and its latest news can be accessed through the company's newsroom at https://ibn.fm/CYBN.
Cybin, founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The company's participation in the conference underscores its active engagement with the investment community and its strategic focus on advancing psychedelic-based therapies through clinical development.
